Colorectal cancer is the third most common and the second deadliest cancer worldwide. To
date, colorectal cancer becomes one of the most important challenges of the health system …

With high prevalence and mortality, together with metabolic reprogramming, colorectal
cancer is a leading cause of cancer-related death. Metabolic reprogramming gives tumors …

CD8+ T cell activation via immune checkpoint blockade (ICB) is successful in microsatellite
instable (MSI) colorectal cancer (CRC) patients. By comparison, the success of …

Background Although cancer immunotherapy is one of the most effective advanced-stage
cancer therapies, no clinically approved cancer immunotherapies currently exist for …

Objective EVA1B, a protein coding gene, is a critical paralog of EVA1A gene. Herein, our
study was conducted to investigate the role of EVA1B in colorectal cancer (CRC) …

Objective The stratification of microsatellite instability (MSI) status assists clinicians in
making treatment decisions for colorectal cancer (CRC) patients. This study aimed to …

Background Immunotherapy, adjuvant chemotherapy, and prognosis of colorectal cancer
are associated with MSI. Biopsy pathology cannot fully reflect the MSI status and …

Mucinous adenocarcinoma (MAC) is a unique clinicopathological subtype of colorectal
cancer, which is characterized by extracellular mucinous components that comprise at least …

There is evidence that methionine enkephalin (MENK), an opioid peptide, promotes anti-
tumor immune responses. In this study, the effect of MENK on colorectal cancer (CRC) and …

Rectal cancer treatment has been evolving ever since the beginning of the 20th century.
Surgery was originally the only available method regardless of the extent of tumor invasion …